Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafenoquine in mild to moderate COVID-19
NCT04533347Phase 2Completed
- Sponsor
- 60 Degrees Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tafenoquine in coronavirus disease 2019 (COVID-19), sponsored by 60 Degrees Pharmaceuticals. Started Feb 2021; status: completed.
02
Drugs
tafenoquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04533347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04533347.